scholarly journals Tardive Dystonia: Clinical Spectrum and Novel Manifestations

1988 ◽  
Vol 1 (1) ◽  
pp. 41-47 ◽  
Author(s):  
R. Jeffrey Davis ◽  
Jeffrey L. Cummings ◽  
Robert W. Hierholzer
Keyword(s):  
Tardive Dyskinesia ◽  
Clinical Spectrum ◽  
Spasmodic Dysphonia ◽  
Tardive Dystonia ◽  
The Face ◽  
Dystonic Disorders

Tardive dystonia was identified in 25 patients: involvement of the face and neck was most common; truncal and limb dystonia were also observed. There were 3 cases of laryngospasm and 2 of spasmodic dysphonia. The latter has not been previously reported as a manifestation of tardive dystonia. In all cases, movements typical of classic tardive dyskinesia could be demonstrated. This group illustrates the variety of dystonic disorders that may occur in conjunction with tardive dyskinesia.

Treatment of tardive dyskinesia

1978 ◽  
Vol 16 (14) ◽  
pp. 55-56
Keyword(s):  
Tardive Dyskinesia ◽  
Late Onset ◽  
Psychiatric Patients ◽  
Term Treatment ◽  
Neuroleptic Drugs ◽  
Abnormal Movements ◽  
Long Term Treatment ◽  
The Face ◽  
Schizophrenic Patients

Neuroleptic drugs cause many forms of extra-pyramidal syndromes. One of these, tardive dyskinesia,1 occurs only after the patient has been taking the drug for some time (‘tardive’ refers to the late onset). The movements are involuntary and repetitive usually involving the face and tongue, but they may also affect the limbs and trunk. Tongue protrusion, licking and smacking of the lips, sucking and chewing movements, grimacing, grunting, blinking and furrowing of the forehead have all been described and attributed to long-continued medication with neuroleptic drugs of the phenothiazine, butyrophenone and thioxanthene groups. The patient can inhibit the movements, but anxiety makes them worse. Many of these symptoms were noticed in schizophrenic patients before neuroleptic drugs were introduced2 and they can occur in otherwise normal untreated elderly people. Nevertheless it is generally accepted that in most cases tardive dyskinesia is an unwanted effect of neuroleptic medication. Despite suggestions to the contrary, the abnormal movements are not necessarily associated with high dosage of neuroleptic drugs or with pre-existing brain damage.3 4 Tardive dyskinesia has been reported in 3–6% of a mixed population of psychiatric patients5 and over half of a group of chronic schizophrenics on long-term treatment.4 The more careful the neurological examination, the greater the apparent incidence.

The management of tardive dyskinesia

1986 ◽  
Vol 24 (7) ◽  
pp. 27-28
Keyword(s):  
Tardive Dyskinesia ◽  
Antipsychotic Drugs ◽  
Disease Process ◽  
Neuroleptic Drug ◽  
Blocking Drug ◽  
Unwanted Effect ◽  
Difficult Condition ◽  
The Face ◽  
Schizophrenic Patients

Dyskinesias are involuntary movements usually of the face and tongue and sometimes of the limbs and trunk. Tardive (delayed) dyskinesia occurs in patients who have been taking an antipsychotic (neuroleptic) drug or, rarely, another central dopamine-receptor-blocking drug such as metoclopramide. It generally occurs only in those treated for longer than a year, although much shorter exposures have been implicated with the antipsychotics. A similar dyskinesia occurred in schizophrenic patients before antipsychotic drugs were introduced, and can occur in healthy untreated elderly people; risk factors include old age, brain damage1 and the schizophrenic disease process.2 Nevertheless, in most patients on an antipsychotic drug (whether psychotic or not), tardive dyskinesia is an unwanted effect of the drug. It occurs in 5–40% of patients on long-term antipsychotic medication.3–5 we discuss here advances in the management of this difficult condition since our last review.6

Delayed and Often Persistent

2016 ◽  
Author(s):  
Susan H. Fox
Keyword(s):  
Side Effects ◽  
Tardive Dyskinesia ◽  
Movement Disorder ◽  
Movement Disorders ◽  
Antipsychotic Drugs ◽  
Dopamine D2 Receptor ◽  
Treatment Options ◽  
D2 Receptor ◽  
Drug Induced ◽  
Tardive Dystonia

Tardive syndromes are drug-induced hyperkinetic movement disorders that occur as a consequence of dopamine D2 receptor antagonism/blockade. There are several types, including classical tardive dyskinesia, tardive dystonia, tardive tics, tardive myoclonus, and tardive tremor, and it is important to the management of these disorders that the type of movement disorder induced is identified. Tardive syndromes can occur with all antipsychotic drugs, including so-called atypical drugs. Patients taking these drugs should be evaluated frequently for side effects. Evaluating the nature of the movement (i.e., chorea or dystonia) is important because treatment options can differ according to the type of dyskinesia present.

Duloxetine-related tardive dystonia and tardive dyskinesia: a case report

2010 ◽  
Vol 32 (6) ◽  
pp. 646.e9-646.e11 ◽  
Author(s):  
Pei-Yi Chen ◽  
Pao-Yen Lin ◽  
Shin-Chiao Tien ◽  
Yung-Yee Chang ◽  
Yu Lee
Keyword(s):  
Case Report ◽  
Tardive Dyskinesia ◽  
Tardive Dystonia

scholarly journals Olanzapine-induced Concurrent Tardive Dystonia and Tardive Dyskinesia in Schizophrenia with Intellectual Disability: A Case Report

2020 ◽  
Vol 18 (4) ◽  
pp. 627-630 ◽  
Author(s):  
Young Min Choe ◽  
So Yeon Kim ◽  
Ihn-Geun Choi ◽  
Guk-Hee Suh ◽  
Dong Young Lee ◽  
...  
Keyword(s):  
Case Report ◽  
Intellectual Disability ◽  
Tardive Dyskinesia ◽  
Tardive Dystonia

scholarly journals Detection of a Putative Novel Papillomavirus Type within a Large Exophytic Papilloma on the Fetlock of a Horse

Pathogens ◽  
2020 ◽  
Vol 9 (10) ◽  
pp. 816
Author(s):  
John S. Munday ◽  
Michael R. Hardcastle ◽  
Melissa Sim
Keyword(s):  
Clinical Presentation ◽  
Equus Caballus ◽  
Pcr Primers ◽  
Clinical Spectrum ◽  
Squamous Papilloma ◽  
Topical Imiquimod ◽  
Numerous Cell ◽  
The Face ◽  
Cell Changes

A 10-year-old horse presented with two 3-cm diameter exophytic masses over the fetlock. Histology was consistent with a hyperplastic squamous papilloma and numerous cell changes consistent with papillomavirus (PV) infection were visible. Partial sequences of PV L1 and E1 ORFs were amplified using consensus PCR primers. The sequences were most similar to Equus caballus type 1 (EcPV1). However, as the sequences were only around 73% similar to EcPV1, they appear to be from a novel PV type that is likely to be within the Zetapapillomavirus genus. The papillomas were treated with topical imiquimod and resolved within 14 weeks. The clinical presentation of the papillomas in the present case had marked differences to the clinical presentation of EcPV-1-induced papillomas, which are typically small, numerous and around the face. Observations from the present case increase the clinical spectrum of PV-induced lesions in this species as well as providing evidence of an additional novel papillomavirus that is able to cause disease in horses.

Sign in / Sign up

Export Citation Format

Share Document